ARTICLE | Company News
Alden Impact Capital, Allenex transplant news
August 29, 2011 7:00 AM UTC
Allenex divested its 50% stake each in NovaHep AB and Recopharma AB to fellow private equity company Alden Impact in exchange for an undisclosed portion of future profits when Alden sells the holdings. Details were not disclosed.
NovaHep focuses on the developing liver stem cell technology to treat liver disease, while Recopharma develops recombinant glycol-proteins for use in vaccine adjuvants and antimicrobials. ...